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Abstract
Herpes virus entry mediator (HVEM) is one of two principal receptors mediating herpes simplex virus (HSV) entry into
murine and human cells. It functions naturally as an immune signaling co-receptor, and may participate in enhancing or
repressing immune responses depending on the natural ligand used. To investigate whether engagement of HVEM by HSV
affects the in vivo response to HSV infection, we generated recombinants of HSV-2(333) that expressed wild-type gD (HSV-2/
gD) or mutant gD able to bind to nectin-1 (the other principal entry receptor) but not HVEM. Replication kinetics and yields
of the recombinant strains on Vero cells were indistinguishable from those of wild-type HSV-2(333). After intravaginal
inoculation with mutant or wild-type virus, adult female C57BL/6 mice developed vaginal lesions and mortality in similar
proportions, and mucosal viral titers were similar or lower for mutant strains at different times. Relative to HSV-2/gD,
percentages of HSV-specific CD8
+ T-cells were similar or only slightly reduced after infection with the mutant strain HSV-2/
gD-D7-15, in all tissues up to 9 days after infection. Levels of HSV-specific CD4
+ T-cells five days after infection also did not
differ after infection with either strain. Levels of the cytokine IL-6 and of the chemokines CXCL9, CXCL10, and CCL4 were
significantly lower in vaginal washes one day after infection with HSV-2/gD compared with HSV-2/gD-D7-15. We conclude
that the interaction of HSV gD with HVEM may alter early innate events in the murine immune response to infection,
without significantly affecting acute mortality, morbidity, or initial T-cell responses after lethal challenge.
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Introduction
Infection of cells with herpes simplex virus (HSV) requires
binding of specific cell surface receptors to viral ligands, with
subsequent fusion of the viral envelope with a cell membrane and
delivery of viral DNA into the cell [1,2]. Although several viral
proteins are capable of mediating attachment, binding of the gD
glycoprotein to one of its receptors is required for subsequent
membrane fusion and productive HSV infection. Human and
murine cells are most efficiently infected by HSV-2 upon
interaction of gD with one of two principal cell surface receptors,
herpes virus entry mediator (HVEM) or nectin-1 [1]. HSV-2 may
use either or both receptors to cause disease after intravaginal
infection of mice [3].
HVEM is a member of the tumor necrosis factor (TNF) receptor
superfamily of proteins [4]. It is expressed in many tissues,
including cells of the immune system, where its known natural
ligands include LIGHT (homologous to lymphotoxins, exhibits
inducible expression, and competes with HSV glycoprotein D for
HVEM, a receptor expressed by T lymphocytes) [5], lymphotox-
in-a [5], B and T lymphocyte attenuator (BTLA) [6,7], and
CD160 [8]. Natural ligands of HVEM enhance or inhibit
lymphocyte activation [9,10]. Engagement of HVEM by LIGHT
increases T-cell activation [5,11,12], while BTLA [6,7] and
CD160 [8] attenuate T-cell activation upon interaction with
HVEM. Recent studies in a systemic model of bacterial infection
suggest that the HVEM-BTLA interaction may predominate to
inhibit early innate immune responses through effects on
proinflammatory cytokine production [13].
Specific alterations in the N-terminal domain of HSV gD can
abolish the functional interaction of gD with HVEM in vitro
without effect on the functional interaction of gD with nectin-1
[14,15,16]. Substitution of the glutamine at position 27 with
proline may distort a strand of gD which forms hydrogen bonds
with a b strand in HVEM [16,17], and various N-terminal
deletions may disrupt a separate interface between amino acids 7-
15 of HSV gD and HVEM [17]. The effects of these mutations on
viral pathogenesis have not been tested in in vivo models.
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binding to HVEM [9], though more recent work suggests that gD
directly competes with BTLA but not lymphotoxin-a or LIGHT for
binding to HVEM [18]. The gD-HVEM interaction also leads to
downregulation of HVEM surface expression, which may alter the
ability of HVEM to participate in immune signaling after infection
[18]. It is difficult to predict how the gD-HVEM interaction might
alter regulatory signals affecting the antiviral immune response.
Several lines of evidence suggest that the gD-HVEM interaction
could enhance an immune response, eitherdirectly or by removal of
a negative signal. The interaction of gD with HVEM can itself
stimulate a response by activation of NF-kB [19,20]. Studies of
candidate DNA vaccines encoding fusion proteins consisting of viral
antigens combined with HSV gD showed that protective antigen-
specific CD8
+ T-cell responses were enhanced by the presence of
gD sequences, providing the domain required for binding to
HVEM was functional [21,22]. Whether this was a direct effect or
due to interference with a negative signal was not studied. Soluble
gD competitively inhibits the BTLA-HVEM interaction [7,18],
presumably due to binding HVEM in the same membrane-distal
cysteine-rich domain(CRD1) [17]to which BTLA [23] and CD160
bind [8]. No studies have directly evaluated how the interaction of
gD and HVEM affects the antiviral immune response during acute
infection with HSV.
We produced and evaluated recombinant HSV-2 viruses unable
to engage HVEM, and applied the murine intravaginal challenge
model to test the pathologic characteristics and acute immune
response induced by these viruses. In contrast to the vaccine
studies described above [21,22], we found that the ability of HSV-
2 strains to engage HVEM, or not, had little effect on
pathogenicity or on certain aspects of the T-cell response to acute
infection. However, mutation of HSV-2 to express gD unable to
interact with HVEM was associated with transiently increased
local chemokine and IL-6 production at early times after infection,
suggesting that wild-type gD may act to dampen these responses
and revealing a novel manner in which HSV-2 may influence the
innate immune response during establishment of infection.
Materials and Methods
Ethics statement
Animal care and use in this study were in accordance with
institutional and NIH guidelines. All studies were approved by the
Animal Care and Use Committee of Northwestern University
(Animal Welfare Assurance A3283-01, Protocol 2009-1730).
Cells and viruses
Vero cells or VD60 cells [24] (Vero cells inducible for HSV-1
gD expression by infection with HSV) were cultured in Dulbecco’s
modification of Eagle’s (DME) medium plus 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin, and were used for
the propagation of virus. Plaque titrations were performed on
Vero cells by standard methods. Chinese hamster ovary (CHO-
K1) cells were initially provided by J. Esko (University of
California, San Diego). CHO-IEb8 cells were obtained by the
stable transfection of CHO-K1 cells with pMLP01, and express
the Escherichia coli lacZ gene under control of the HSV-1 ICP4
promoter [4]. CHO-IEb8 cells expressing HSV receptors were
grown in Ham’s F12 medium supplemented with 10% fetal bovine
serum. Cells were transfected with human HVEM [4], human
nectin-1 [25], human nectin-2 [26], murine HVEM [16], murine
nectin-1 [16], or human 3-O-sulfotransferase-3B [27] as described.
HSV-2 strain 333 was isolated from a genital lesion and
underwent limited passage in human cells [28]. The virus was
plaque purified and passaged no more than three times in Vero
cells.
Plasmids
Plasmids encoding HSV entry receptors included pcDNA3-based
constructsasfollows:pBEC10 expressinghuman HVEM[4],pBG38
expressing human nectin-1 [25], pMW20 expressing human nectin-2
[26], a plasmid encoding human 3-O-sulfotransferase-3B whose
expression generates HSV-1 entry receptors [27], pDS106 expressing
mouse HVEM [16], and pCR13 expressing mouse nectin-1 [16].
Plasmid pMY152 contains the HSV-2(333) gD ORF (US6) and
portions of the flanking genes (encoding gJ and gI) cloned into
pUC19 between the EcoRI and HindIII sites [14]. The
QuikChange II site-directed mutagenesis kit (Stratagene) was used
to add two 47-base pair FRT sites [29] immediately upstream and
downstream of the US6 gene, generating pMY153. A GFP ORF,
flanked by two 34-bp minimal FRT sites, was also generated by
using pEGFP-N1 (Clontech) as a template to obtain pMY151.
pMY155 was obtained by replacing the gD ORF of pMY153 with
the GFP ORF from pMY151. The FRT sequence contains an
XbaI site, allowing switching of sequences bounded by FRT sites.
The gD ORF flanked by partial FRT sites was subcloned into
pUC19 to generate pMY160. Targeted mutations in gD were
generated by using pMY160 as a template and the QuikChange II
kit. The mutated alleles of gD were then subcloned into pMY155
replacing the GFP ORF. All of the plasmids produced for this
study were verified by DNA sequencing of the inserts. The plasmid
encoding yeast FLP recombinase, pOG44, was purchased from
Invitrogen.
Construction of HSV-2(333) mutants
Recombinant viruses were obtained from cells cultured in six-
well plates that had been cotransfected with HSV-2 genomic DNA
and the appropriate plasmid DNAs by using Lipofectamine 2000
(Invitrogen) in serum-free medium for 6 h with a change to
medium containing 10% FBS overnight. Cells were then
incubated with medium containing 1% heat-inactivated FBS for
5 days and harvested and sonicated to obtain virus stocks. The
recombinant virus HSV-2/gD, which carries the wild-type gD
ORF flanked by FRT sites, was constructed in several steps by
methods previously applied to HSV-1 [15]. A GFP-expressing
HSV-2 lacking the gD gene (HSV-2/GFP) was obtained by
cotranfecting VD60 cells with genomic HSV-2(333) DNA and
pMY155, and plaque-purification for 4 rounds on VD60 cells.
The resulting virus was confirmed to be unable to form plaques on
Vero cells. HSV-2/FRT was obtained by transfecting VD60 cells
with pOG44 and infecting with HSV-2/GFP, leading to FLP
recombinase-mediated removal of the GFP gene. Resulting GFP-
negative virus was plaque-purified on VD60 cells. HSV-2/gD was
obtained by co-transfecting Vero cells with HSV-2/FRT DNA,
pOG44, and circularized DNA containing the wild-type HSV-
2(333) ORF with ends joined by a single 47-bp FRT site (obtained
from an XbaI digest of pMY153, with subsequent self-ligation of
the 1.2 kb band and DNA clean-up). Plaques were screened 5 days
after transfection, and a purified recombinant obtained after 4
rounds of plaque-purification. HSV-2/gD-Q27P and HSV-2/gD-
D7-15 were obtained using similar methods. The recombinant
viruses were plaque-purified on Vero cells. Sequences of the gD
ORFs were determined from four independent clones obtained by
PCR amplification and TA cloning.
Single-step replication kinetics
Vero cells were inoculated at 5 plaque-forming units (PFU) per
cell. After 2 h, the cells were washed and treated with 0.1 M
HSV-2 gD-HVEM Interaction Influences Chemokines
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viruses, washed again, and incubated with fresh medium
containing 1% heat-inactivated FBS. At different times after
inoculation, the cells were scraped into the medium containing
released viruses and lysed by sonication. Titers were then
determined by plaque assay on Vero cells.
Viral entry assay
Assays for viral entry were as described [4]. Briefly, CHO-IEb8
cells expressing one of the entry receptors were grown in 96-well
plates, inoculated with serial dilutions of the recombinant viruses,
and incubated for 6 h. The cells were then washed, permeabilized,
and incubated with the b-galactosidase substrate o-nitrophenyl b-
d-galactopyranoside (ONPG, Sigma). The reaction was monitored
at 410 nm to quantitate viral entry using a Spectra Max250 plate
reader (Molecular Devices).
Mouse intravaginal HSV-2 challenge
Female C57BL/6 mice were purchased from Jackson Labs at
between 6–10 weeks of age, and infected before 12 weeks of age.
Mice were maintained in specific-pathogen-free conditions until
infection and then were transferred to a containment facility.
Female mice were rendered susceptible to infection by
subcutaneous injection with 2.5 mg of medroxyprogesterone
acetate (Depo-ProveraH, Pharmacia) in phosphate-buffered saline
(PBS) 6 days prior to challenge [30]. Mice were anesthetized with
tribromoethanol [31] or ketamine-xylazine, vaginas were swabbed
to clear secretions, and virus was delivered intravaginally via
micropipette in 20 mL total volume. Virus was diluted in PBS
containing 1% inactivated calf serum and 0.1% glucose to deliver
6610
5 PFU/mouse except as indicated otherwise.
Mice were examined daily for external lesions (hair loss,
inflammation, and perineal skin lesions) and neurological signs of
disease (abdominal distention indicative of fecal or urinary
retention or hind-limb paralysis) or other signs of morbidity
(hunched posture, lethargy, dehydration). Those exhibiting severe
morbidity were sacrificed. Surviving mice were sacrificed at the
indicated times after infection, and tissues harvested for analysis.
Tissues used for virus titration were weighed, snap frozen, and
stored at 280uC until analysis by plaque assay. The organs were
homogenized in 2.5 ml of cold PBS, 1% calf serum, 0.1% glucose
using disposable homogenizers, sonicated briefly, and centrifuged
at low speed to remove tissue debris, and the supernatant was
serially diluted for PFU quantification on Vero cells. Results are
presented as PFU per g of tissue.
Isolation of lymphocytes
Lymphocytes were isolated from spleens, draining lymph nodes,
vaginal tissue, and spinal cord tissue. Spleens and draining lymph
nodes from each mouse were separately homogenized in RPMI-
1640 with 2% heat-inactivated FBS. Red blood cells were lysed
with ACK buffer. Cells were washed, counted, and maintained in
complete medium (RPMI-1640, 10% FBS, 1 mM sodium
pyruvate, 0.1 mM non-essential amino acids, 1% penicillin-
streptomycin, and 20 mM b-mercaptoethanol) for ELISPOT or
flow cytometric assay.
Vaginal tissue was processed by a protocol similar to that
described by Gierynska et al [32]. Isolated tissue was washed in
Hanks balanced salt solution (HBSS), cut into small pieces, and
incubated in RPMI 1640 with collagenase D (1 mg/mL) for
1 hour at 37uC with gentle agitation. Digested tissue was pressed
through a cell strainer, washed in RPMI-1640 with 2% heat-
inactivated FBS, and the cells counted and resuspended in
complete medium.
Spinal cord tissue was processed by a protocol similar to
Vanderlugt et al [33]. Tissue was extruded from the spinal column
by flushing with PBS, and processed by collagenase digestion using
the same protocol as for vaginal tissue. Cells were then
homogenized through a cell strainer, and the resulting suspension
was spun down. Cells from spinal cord tissue were then
resuspended in 30% Percoll and layered over 70% Percoll in
15 cc conical tubes. Gradients were centrifuged at 5006g for
20 minutes at room temperature, and cells collected from the
30:70 interface. These cells were washed, counted, and resus-
pended in complete medium.
Measurement of murine T-cell responses by ELISPOT
For IFN-c ELISPOT assays, plates (Millipore) were coated with
rat IgG1 anti-murine IFN-c mAb (clone R4-6A2, BD Pharmin-
gen) at 10 mg/ml in 50 ml/well of 0.2 M carbonate/bicarbonate
buffer, pH 9.4, and held at 4uC for use in 12–48 hours. Plates
were washed three times in PBS and blocked for 2 hours at 37uC
with RPMI-1640 with 10% heat-inactivated FBS. Splenocytes
from an uninfected mouse were added to each well at 5610
5 cells/
well in 50 mL complete medium to serve as antigen-presenting
cells. Cells isolated from spleen, lymph nodes, vaginal tissue, and
spinal cord tissue were separately added in 50 mL of complete
medium at different dilutions to provide less than or equal to
5610
5 cells/well. To evaluate CD8
+-specific responses, cells were
stimulated with the H-2K
b immunodominant peptide in glyco-
protein gB (SSIEFARL) [34], which spans amino acids 496–503 in
HSV-2 (based on strain HG52) [35]. In separate experiments,
CD4
+ T-cell responses were evaluated by adding heat-inactivated
(56uC, 2 hours) HSV-2(333) to each well at an approximate MOI
of 1, based on the titer before heating. For some experiments,
lymphocytes from draining lymph nodes or vaginal mucosal tissue
isolated from infected animals were enriched for CD4
+ lympho-
cytes, using antibody-conjugated magnetic beads (Miltenyi Biotec)
according to the manufacturer’s instructions. Control wells were
stimulated with concanavalin A at 5 mg/mL (positive control) or
medium only (negative control).
After 18–24 hours at 37uC in a humidified 5% CO2 incubator,
plates were washed with water and three times with PBS.
Detection used biotinylated rat anti-mouse IFN-c (BD Pharmin-
gen) at 1 mg/ml in 50 ml/well of PBS, incubated at room
temperature for two hours. After 5 washes with PBS, alkaline
phosphatase-streptavidin (Biorad), diluted 1:1000 in PBS was
added in 50 ml for 60 minutes at room temperature. After 5
washes, substrate (Biorad) was added at 50 ml/well for 3–
5 minutes. Reactions were stopped with water and plates air-
dried and counted using an automated plate reader (Cellular
Technology Ltd.). ELISPOT data are reported as means of
duplicate measurements, calculated from the linear part of a
dilution curve comparing spot-forming units (SFU) per well to
serial dilutions of responder cells. Negative control wells were less
than 5 SFU/10
6 responder cells, and values below this were
considered negative.
Measurement of murine T-cell responses by flow
cytometry
Cells to be analyzed by flow cytometry were washed and
resuspended in FACS buffer. Surface labeling included fluores-
cently conjugated antibodies to murine CD3 or CD4 and CD8,
and DimerX-PE reagent (BD Biosciences) pre-loaded with the
gB496–503 peptide according to the manufacturer’s instructions.
Cells were analyzed using an LSR II flow cytometer and FACS
Diva software (BD Biosciences).
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chemokine levels
Vaginal secretions were collected from infected mice at
indicated times. Sterile PBS was instilled intravaginally in a
40 mL volume and pipetted in and out 2–3 times (see e.g. [36]).
This was repeated twice and samples pooled for analysis. Samples
were stored at 220uC until analysis using a multiplex bead assay
(Millipore Milliplex assay), conducted according to the manufac-
turer’s instructions and read using a Luminex 100 plate reader.
Statistical Tests
Kaplan-Meier survival analysis was performed using the Gehan-
Breslow test. Geometric means of values for viral infectious units in
tissues were compared using the unpaired Student’s t test or Mann
Whitney rank-sum test. For ELISPOT and flow cytometric assays,
means of spot-forming units per 10
6 responder cells or mean
percentages of fluorescently labeled cells within a population were
compared between experimental groups using the unpaired
Student’s t test. For Luminex assays, mean concentrations of
cytokines or chemokines were also compared between experimen-
tal groups using the unpaired Student’s t test.
Results
HSV-2 gD modifications do not alter in vitro replication
We replaced the gD ORF of HSV-2(333) with an ORF
including the native gD gene flanked by FRT sites. The resulting
virus, HSV-2/gD, replicated on Vero cells with kinetics indistin-
guishable from the parent strain (Fig. 1A). We also generated
recombinant HSV-2 viruses containing targeted mutations in the
HVEM-binding regions of gD, HSV-2/gD-Q27P and HSV-2/
gD-D7-15. In vitro replication of these recombinants on Vero cells
was comparable to that of the parental HSV-2(333) strain and also
of the HSV-2/gD virus, which expresses wild-type gD (Fig. 1B).
Selective loss of HVEM usage for cell entry by HSV-2/gD-
Q27P and HSV-2/D7-15
CHO cells are generally resistant to infection with HSV. To test
the ability of the different recombinant viruses to infect cells using
different HSV receptors, we assayed viral entry using CHO-IEb8
cells transfected with plasmids encoding different HSV receptors
(Fig. 2). Overall, entry of HSV-2(333) and HSV-2/gD was
comparable for each of the different receptors tested. Entry of the
HSV-2/gD-Q27P and HSV-2/gD-D7-15 viruses was severely
impaired in cells expressing either human or murine HVEM.
Entry of all viruses into cells expressing human nectin-1 was
comparable. The HSV-2/gD-Q27P and HSV-2/gD-D7-15 virus-
es were minimally impaired for entry into cells expressing murine
Figure 1. Effects of FRT flanking regions and gD mutations on
HSV-2 replication in Vero cells. (A) Replication kinetics of HSV-2/gD
and HSV-2(333) in Vero cells. Replicate cultures of cells were inoculated
with 5 PFU per cell of each virus. Cell lysates were prepared at the times
indicated after viral inoculation. Virus yields as a function of time after
inoculation were determined by plaque assay on Vero cells with
duplicate determinations. (B) Replication kinetics of HSV-2/gD and
mutant HSV-2 viruses in Vero cells. Cells were infected and assays
completed as in (A).
doi:10.1371/journal.pone.0016122.g001
Figure 2. Viral entry into cells expressing different HSV-2 gD
receptors. Parental HSV-2 and the recombinant HSV-2 mutants were
tested for entry into CHO-IEb8 cells expressing human nectin-1, human
nectin-2, murine nectin-1 (mNectin-1), human HVEM, murine HVEM
(mHVEM), or human 3-O-sulfotransferase-3B (which generates the HSV
entry receptor 3-O-S HS). Cells in 96-well plates (5610
4 cells per well)
were inoculated with serial dilutions of the viruses, with input doses as
indicated. Effective viral doses (amount of virus that actually makes
contact with a cell) are less than the input because of the necessity of
using a relatively large inoculum per monolayer surface area in the
small wells. After 6 h, the cells were washed and lysed for the
quantitation of b-galactosidase activity (expressed from the cell
genome as a stably transfected lacZ gene under control of an HSV
immediate-early promoter) as a measure of viral entry. Values plotted
are OD at 410 nm of the o-nitrophenyl b-d-galactoside reaction product
as a function of viral dose. The means of triplicate determinations with
SDs for one representative experiment are shown. Similar results were
obtained in two additional experiments.
doi:10.1371/journal.pone.0016122.g002
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expressing human nectin-2 relative to the other viruses. Murine
nectin-2 is not a receptor for HSV-1 or HSV-2 entry [37] and was
not tested here. None of the viruses used 3-O-sulfated heparan
sulfate efficiently for entry, as expected [27].
Minimal effects of the gD mutations on clinical lesions,
mortality, and viral replication after intravaginal
challenge in mice
Mice infected intravaginally with HSV develop vaginal
erythema, genital and perigenital lesions, hair loss, and may
succumb to lethal effects of viral invasion of sensory and
autonomic nerves [30]. We observed female mice for development
of visible clinical lesions or mortality for up to 18 days after
intravaginal inoculation with different amounts of HSV-2/gD,
HSV-2/gD-Q27P, or HSV-2/gD-D7-15 (Fig. 3). At all doses
tested, subtle but statistically significant delays in time to
development of external lesions were noted in groups of mice
inoculated with HSV-2/gD-Q27P compared with HSV-2/gD. At
the lowest inoculum (2610
5 PFU), development of external lesions
was also mildly delayed in the group of mice inoculated with HSV-
2/gD-Q27P compared with HSV-2/gD-D7-15. There were no
statistical differences in survival after inoculation with any of the
viruses at any of the doses tested.
Viral replication in the vaginal mucosa and spinal cords was
measured by plaque assay at different times after inoculation with
6610
5 PFU/mouse of the different recombinant viruses. We chose
to test this intermediate dose of virus in these and subsequent
experiments, as it was the lowest dose tested that led to clinical
disease in virtually all mice inoculated. Vaginal titers were lower in
mice receiving the HSV-2/gD-Q27P and HSV-2/gD-D7-15
viruses at several time points when compared with mice receiving
HSV-2/gD (Fig. 4). In the spinal cords, peak titers were lower in
mice receiving the HSV-2/gD-Q27P virus as compared with the
HSV-2/gD and HSV-2/gD-D7-15 viruses, and titers seven days
after inoculation were lower in the HSV-2/gD-Q27P and HSV-2/
gD-D7-15 groups relative to the HSV-2/gD group. However,
these differences did not dramatically affect clinical lesions or
mortality (Fig. 3).
Acute anti-HSV T-cell expansion in infected tissues is
similar after intravaginal inoculation of mice with HSV-2/
gD and HSV-2/gD-D7-15
Because engagement of HVEM on T-cells by its natural ligands
may augment (in the case of LIGHT) or attenuate (in the case of
BTLA or CD160) immune responses [9,38,39,40,41], the effect of
the D7-15 deletion in gD on the T-cell responses occurring within
9 days after HSV infection was investigated. Initial focus was on
the CD8
+-specific antiviral response, as this response was strongly
influenced by the presence of gD in a vaccine model [22]. Since
more than 70% of the CD8
+ T-cell response in C57BL/6 mice is
directed against a single epitope in the gB glycoprotein [34]
(spanning amino acids 496–503, based on the sequence of HSV-2
strain HG52 [35]), we used this response as a surrogate for the
overall HSV-specific CD8
+ T-cell response. IFN-c-producing T-
cells responding to the gB496–503 peptide as detected by ELISPOT
were generally present in similar relative amounts in spleen,
draining lymph nodes, vagina, and spinal cord over the first 9 days
Figure 3. Effects of mutations in gD on clinical disease after intravaginal inoculation of mice. Top panels – Percentage of mice remaining
free of external lesions at the days indicated after virus inoculation. Bottom panels – Percentage of mice remaining alive at the days indicated after
virus inoculation. Mice were sacrificed as soon as potentially lethal signs of neurological disease became evident. There were 9–10 mice per group for
doses of 2610
5 or 6610
5 PFU/mouse, and 4–8 mice per group for 1.8610
6 PFU/mouse. The asterisks indicate slight but statistically significant
differences in the time to development of lesions for mice inoculated with HSV-2/gD-Q27P compared with HSV-2/gD and between HSV-2/gD-Q27P
and either of the other viruses at the lowest dose.
doi:10.1371/journal.pone.0016122.g003
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left column). Neither total cell counts nor total calculated numbers
of IFN-c-producing T-cells in each tissue type at each time point
differed between mice infected with HSV-2/gD or HSV-2/gD-
D7-15 (Figure S1).
Slight differences were observed in the percentage of CD8
+ T-
cells recognizing the gB496–503 epitope as measured by flow
cytometry after infection with the different viruses (Fig. 5, right
column). Expansion was lower in splenocytes from mice infected
with HSV-2/gD-D7-15 relative to HSV-2/gD days 5 and 9 after
infection, in draining lymph nodes day 3 after infection, and in
spinal cord cells day 9 after infection. No statistical differences were
observed in the overall percentage of CD8
+ T-cells in any tissue at
any time, nor were there differences in the total calculated number
of CD8
+ T-cells recognizing the gB496–503 epitope (Figure S1).
HSV-specific CD4
+ T-cells migrate into infected vaginal tissue
and produce IFN-c, with peak responses occurring 4–5 days after
infection [42]. These cells are critical for CTL entry into infected
mucosal tissue [43]. Prior studies have shown that CD4
+ T-cells
are more sensitive to BTLA-mediated inhibition of TCR-mediated
activation than CD8
+ T-cells [44]. Accordingly, we investigated
the effect of the HSV gD-HVEM interaction on the HSV-specific
CD4
+ T-cell response in draining lymph nodes and vaginal
mucosa. Similar levels of IFN-c-producing cells responding to
heat-inactivated virus were present in CD4
+-enriched fractions of
cells isolated from draining lymph nodes of infected mice 5 days
after inoculation with either HSV-2/gD or HSV-2/gD-D7-15
(Fig. 6). We did not detect IFN-c-producing CD4
+ T-cells in
sufficient numbers from mucosal tissue to quantify differences
between the viruses at this time point using this assay.
Chemokine production in vaginal secretions is altered by
engagement of HVEM
HVEM engagement by LIGHT leads to signaling through the
NF-kB family of transcription factors, subsequently influencing
numerous downstream genes encoding adhesion molecules, che-
mokines, and cytokines [45]. Recently, in vitro studies of human
fibroblasts have suggested that LIGHT signaling through HVEM
enhances IFN-c-dependent chemokine production [46]. We tested
chemokine and cytokine levels in vaginal secretions from mice
infected with HSV-2/gD or HSV-2/gD-D7-15 at different times
after infection. Levels of the chemokines CXCL9 (also known as
monokine activated by IFN-c, or MIG), CXCL10 (also known as
interferon-inducible protein of 10 kD, or IP-10), and CCL4 (also
known as MIP-1b) were measured at two- to ten-fold higher levels
day 1 after infection with HSV-2/gD-D7-15 relative to HSV-2/gD
(Fig. 7A–C); these differences did not persist at later times. Levels of
thecytokineIL-6 weretwenty-foldhigherthefirstdayafterinfection
with HSV-2/gD-D7-15 relative to HSV-2/gD (Fig 7D). Mean
IFN-c levels were measured to be higher the day after infection with
HSV-2/gD-D7-15 (3616424 pg/mL vs. 20626 pg/mL after
infection with HSV-2/gD), but this difference did not reach
statistically significance (p=0.21). Levels of other chemokines and
cytokines tested (IL-10, IL-12p40, IL-12p70, CCL2 [MCP-1],
CCL3 [MIP-1a], CCL11 [eotaxin], CXCL1 [KC], CXCL2 [MIP-
2], and VEGF) did not differ significantly between groups of mice.
Discussion
The major conclusion from our study is that vaginal infection of
mice with a strain of HSV-2 expressing a mutant form of gD
unable to engage HVEM leads to a transient increase in mucosal
chemokine (CXCL9, CXCL10, and CCL4) and IL-6 levels when
compared to infection with HSV-2 expressing wild-type gD. Our
results suggest that the interaction of wild-type gD and HVEM
during murine intravaginal infection with HSV-2 may initially
suppress the production of these early inflammatory proteins,
demonstrating an additional role for this interaction distinct from
viral entry. This increase in chemokine and cytokine secretion was
associated with a small decrease in replicating virus at the mucosa.
We noted no effects of our gD mutations on single-step growth in
Vero cells (Fig. 1), and observed the expected impairment of entry
intocellsexpressingmurineorhumanHVEM(Fig.2).Aslightentry
defect was measured in CHO cells expressing murine nectin-1
(Fig. 2). This entry defect may have contributed to our observation
of lower vaginal and spinal cord titers at some time points after
infection with viruses containing gD mutations relative to virus with
wild-type gD (Fig. 4). It is also possible that the transient increases in
local chemokine and IL-6 production we measured could have
affected replication of these viruses, most plausibly through effects
on innate immune responses. Although the primary function of
chemokines is to promote migration of immune effector cells to sites
of inflammation [47,48], certain chemokines may also influence the
maturation and function of the innate immune response [49]. This
has been demonstrated in murine CMV infection, where effective
NK cell functional responses depend on CCL3 [50]. Human NK
cells migrate in response to CCL4, CXCL9, and CXCL10, and
may increase cytotoxicity in response to CCL4 and CXCL10 [51],
suggesting relevance of our observations. A direct antiviral effect of
Figure 4. HSV-2 titers in relevant tissues after infection. Viral
titers were measured in vaginal tissue (top) or spinal cords (bottom)
from mice sacrificed on the days indicated after virus inoculation. The
mice were inoculated intravaginally with 6610
5 PFU of HSV-2/gD
expressing wild-type gD or recombinant HSV-2 (HSV-2/gD-Q27P or
HSV-2/gD-D7-15). Symbols denote individual mice; horizontal lines are
means for each group. Brackets show groups with statistically
significant differences (p,0.05) in mean titers.
doi:10.1371/journal.pone.0016122.g004
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observation of increased IL-6 after infection with mutant HSV-2 is
also unlikely to have directly led to diminished mucosal viral
replication of our mutant strains, as exogenous IL-6 does not alter
viralreplicationinvitro,andinamurineophthalmicmodelofdisease
the lack of IL-6 does not lead to increased HSV replication in vivo
[52]. However, IL-6-deficient micehave higher mortality than wild-
type mice after ocular inoculation with HSV [52].
Figure 5. Analysis of HSV-specific CD8
+ cells in relevant tissues after infection. Cells were obtained from mice inoculated with HSV-2/gD or
HSV-2/gD-D7-15 (0.6610
6 PFU/mouse). Left panels: Number of IFN-c-producing T-cells responding to the immunodominant gB496–503 epitope
(SSIEFARL), per 10
6 leukocytes extracted from the tissues indicated on the days indicated after virus inoculation. Cells isolated from the different
tissues were evaluated by IFN-c ELISPOT. There were no statistical differences in mean values between groups of mice at any time point. Right panels:
Quantitation of gB496–503-specific CD8
+ T-cells extracted from the tissues indicated on the days indicated after virus inoculation, expressed as a
percentage of CD8
+ cells. Cells isolated from the different tissues were labeled with fluorescent antibodies to murine CD8 and either CD3 or CD4,




2 cells determined. Results are expressed at the means and SD of 3–12 mice per time point; mean values with statistical
differences are highlighted, with p values reported above the data.
doi:10.1371/journal.pone.0016122.g005
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increased chemokine and IL-6 production and slightly diminished
viralreplicationrelativetovirusexpressingwild-typegD,weobserved
only minor effects on development of external lesions (Fig. 3), and did
not detect differences in mortality (Fig 3) or T-cell recruitment to
infected tissue (Figs. 5–6). The transient alteration in chemokine
production we measured may not have been of sufficient duration to
promote detectable differences in cellular immune responses. It is also
possible that the relatively high titers of HSV-2 needed to establish
productive infection in C57BL/6 mice may promote an infiltrating
cellular immune response through mechanisms not altered by the
mutations made in our mutant strains, limiting our ability to detect
any differences between viruses expressing wild-type or mutant gD.
Thedifferencesinchemokineproductionorcellularinfiltrationmight
be magnified at lower doses of virus, or alternatively may take on
added importance during viral reactivation, which is difficult to study
in this model (discussed further below).
CXCL9 and CXCL10 levels in vaginal washes were signifi-
cantly different after infection with our different strains (Fig 7A–B).
Both chemokines are known to be important in control of mucosal
HSV infection [53,54]. Virus is able to reach the central nervous
system more quickly after vaginal infection in mice deficient in
CXCL10, and trafficking of NK cells and HSV-specific CD8
+
Figure 6. Analysis of CD4
+ cells obtained from draining lymph
nodes. Draining lymph nodes were isolated from mice inoculated
intravaginally 5 days prior with HSV-2/gD or HSV-2/gD-D7-15 (0.6610
6
PFU/mouse). IFN-c-producing T-cells were detected by ELISPOT based
on response to inactivated HSV-2(333). Representative data from one of
three independent experiments are shown, and are expressed as the
mean and SD from three mice per group.
doi:10.1371/journal.pone.0016122.g006
Figure 7. Chemokine levels assessed by Luminex assay collected at indicated times from vaginal lavages. Panels A–D show levels of
CXCL9, CXCL10, CCL4, and IL-6, respectively, measured from groups of mice days 1, 3, and 5 after infection. Data are pooled from two independent
experiments with at least three mice per group, and represented as mean 6 standard deviation.
doi:10.1371/journal.pone.0016122.g007
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+ T-cells) to infected tissue is impaired in both
CXCL9 and CXCL10-deficient mice [54]. We did not measure
NK cell infiltration in these experiments, and did not assess
chemokine levels in vaginal tissue itself or in other relevant tissues,
such as draining lymph nodes or nervous system. Alterations in the
inflammatory chemokine response in the lymph nodes and
nervous system have been found to affect viral clearance and
pathogenicity in the mouse intravaginal infection model [54,55].
Further experiments are underway to assess whether infection with
our mutant viruses alters chemokine gradients important in
orchestrating protective cellular immune responses, and whether
functional NK cell or adaptive cellular responses are altered.
We undertook these studies to better understand whether the
ability of HSV gD to interact with HVEM could alter immune
responses. Although HVEM mediates both positive and negative
immune signals [10], our observations are most consistent with the
hypothesis that early in infection, gD interferes with a positive signal
through HVEM initiated by LIGHT. Signaling through HVEM
activates inflammatory genes through the transcription factors AP-1
and NF-kB [10,56]. Production of CXCL9 [57] and CXCL10 [58]
are promoted by NF-kB activation, and the ccl4 promoter region has
an AP-1 site which acts as a positive regulator [59]. LIGHT induces
cytokine and chemokine production after engaging HVEM (even in
the absence of IFN-c) [45], and treatment of human gingival
fibroblasts in vitro with LIGHT augments IFN-c -induced chemokine
production [46]. Together, these observations suggest that HVEM-
mediated activation of AP-1 and NF-kB can augment production of
CXCL9, CXCL10, and CCL4 in some cell types. HVEM is
expressed by epithelial cells in addition to immune cells, and its
expression may increase after HSV infection in certain epithelial cells
[60]. However, epithelial cells have not been reported to express the
inhibitory ligands BTLA or CD160. Therefore, although HSV gD
may compete with both LIGHT [5] and BTLA [7] for binding to
HVEM and/or rapidly downregulate surface expression of HVEM
to decrease LIGHT- or BTLA-mediated signaling [18], our
observations of increased chemokine responses after infection with
virus mutated to remove interaction with HVEM are consistent with
the notion that wild-type gD may interfere with a proinflammatory
signal. This is in contrast to a recent study of systemic bacterial
infection using mice deficient in LIGHT, HVEM, or BTLA, which
suggested a critical role for BTLA in inhibiting early innate
proinflammatory responses [13]. It is possible that the results of the
previously mentioned studies suggesting an adjuvant effect of gD in
heterologous DNA vaccine constructs may also be more easily
explained by interference by gD with a negative signal [21,22].
The chemokines CXCL9 and CXCL10 have recently been shown
to be critical to infiltration of antiviral CD8
+ T-cells after mucosal
HSV infection [43], and also influences cytolytic activity of these cells
[61]. The transient alteration in chemokine response we observed did
not lead to altered antiviral CD8
+ infiltration, but may be relevant to
HSV cellular immunity during secondary challenge or during HSV
reactivation at the mucosa. The latter process is not easily evaluated
in the mouse model; however, for the virus to reactivate and replicate
in mucosal or cutaneous epithelia in latently infected individuals,
there needs to be at least some suppression of existing cellular
immune responses. Viral suppression of chemokine cues directing the
antiviral memory response may be one such mechanism.
The alterations in the N-terminal domain of HSV-2 gD were
expected from prior studies to abolish the interaction of HSV with
HVEM [14,15,16]. However, viruses expressing these altered forms
of gD had not been generated or tested previously, either in cultured
cells or for pathogenesis studies in mice. Although the prior studies
and crystallographic data on HSV-1 gD bound to HVEM [17]
suggest that these N-terminal regions of HSV-2 gD are important for
binding HVEM, it is not yet known how similar are the structures of
HSV-1andHSV-2gD[16],andtheirsecondarystructuresmayhave
important differences [62]. Our results support a similar importance
of the Q27 side chain in the functional interaction of HSV-2 gD with
HVEM as seen for HSV-1 [16]. The enhanced use by HSV-2/gD-
Q27P of nectin-2 as an entry receptor (Fig. 2) is also of virologic
interest; wild-type HSV-2 but not HSV-1 can use human nectin-2 as
an entry receptor [63], and mutations in the N-terminal domain of
HSV-1 can confer ability to use nectin-2 for entry [15,16,64,65].
In summary,wehave confirmedthat mutationsinthe N-terminal
domainof HSV-2 gD canabrogate viral entry via HVEM. We have
tested mutant HSV-2 in vivo, and show that these mutations alter
early chemokine and cytokine production at the mucosa and are
associated with reduced mucosal viral replication, but have minimal
effects on pathogenicity and acute T-cell responses. These results
have implications on the understanding of HSV pathogenicity in
vivo, and suggest that alteration of the HVEM-binding domains of
HSV gD may potentiate acute anti-viral innate immune responses.
Supporting Information
Figure S1 Numbers of HSV-specific CD8
+ cells in relevant
tissues after infection. C e l l sw e r eo b t a i n e df r o mm i c ei n o c u l a t e d
with HSV-2/gD or HSV-2/gD-D7-15 (0.6610
6 PFU/mouse). Left
panels: Total numbers of IFN-c-producing T-cells responding to the
immunodominant gB496–503 epitope (SSIEFARL), calculated from
percentages of leukocytes extracted from the tissues indicated on the
days indicated after virus inoculation. Cells isolated from the different
tissues were evaluated by IFN-c ELISPOT. There were no statistical
differences in mean values between groups of mice at any time point.
Right panels: Numbers of gB496–503-specific CD8
+ T-cells extracted
from the tissues indicated on the days indicated after virus
inoculation, calculated from percentages of CD8
+ cells. Cells isolated
from the different tissues were labeled with fluorescent antibodies to
murineCD8andeitherCD3orCD4,alongwithfluorescentlytagged
DimerX loaded with gB496–503. Lymphocytes were gated based on




2 cells determined. Results are expressed at the means
and SD of 3–12 mice per time point. There were no statistical
differences in mean values between groups of mice at any time point.
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